Axsome Therapeutics, INC Form 4 insider transactions

Axsome Therapeutics Director Mark Coleman exercised 5,193 stock options at $8.02 per share, increasing his direct beneficial ownership to 53,405 shares.

Axsome Therapeutics CEO Herriot Tabuteau exercised expiring stock options and subsequently sold the acquired common stock shares under a pre-approved 10b5-1 plan.

Axsome Therapeutics' Chief Financial Officer, Nick Pizzie, exercised stock options and subsequently sold 12,000 shares of common stock under a pre-approved 10b5-1 plan.

Axsome Therapeutics' Chief Commercial Officer, Ari Maizel, exercised stock options and subsequently sold 7,500 shares of common stock for a significant gain.

Axsome Therapeutics CEO Herriot Tabuteau executed a series of pre-planned transactions, exercising expiring stock options and subsequently selling the acquired common stock.

Axsome Therapeutics Director Mark E. Saad exercised stock options and subsequently sold the acquired common stock, as disclosed in a recent Form 4 filing.

Axsome Therapeutics CEO Herriot Tabuteau exercised expiring stock options and subsequently sold the acquired shares for a significant gain under a 10b5-1 plan.

Axsome Therapeutics CEO Herriot Tabuteau exercised stock options and subsequently sold the acquired shares for a significant profit under a pre-approved 10b5-1 trading plan.

Axsome Therapeutics CEO Herriot Tabuteau exercised stock options and subsequently sold the acquired shares as part of a pre-approved 10b5-1 plan.

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, exercised stock options and subsequently sold 10,000 common shares for a weighted average price of $115.96 per share.

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, exercised stock options and subsequently sold 45,783 shares of common stock on September 16, 2025, under a pre-approved 10b5-1 plan.

Axsome Therapeutics CEO Herriot Tabuteau executed planned sales of common stock following the exercise of expiring stock options in mid-September 2025.

Axsome Therapeutics Director Mark Coleman increased his direct beneficial ownership of common stock through open market purchases totaling 1,575 shares.

Axsome Therapeutics Director Mark E Saad exercised stock options and subsequently sold 9,127 shares for a significant gain under a pre-approved 10b5-1 plan.

Axsome Therapeutics Director Roger Jeffs sold 13,464 shares of common stock for a weighted average price of $123.68 per share, completing a pre-approved 10b5-1 plan.

Axsome Therapeutics Director Roger Jeffs has scheduled the sale of 60,000 shares of common stock for approximately $7.3 million in August 2025 through a pre-approved 10b5-1 trading plan.

Axsome Therapeutics Director Roger Jeffs sold a total of 36,694 shares of common stock in two transactions in August 2025 under a pre-approved 10b5-1 plan.

Axsome Therapeutics' General Counsel, Hunter R. Murdock, completed pre-scheduled transactions under a 10b5-1 plan, exercising stock options and immediately selling the acquired common stock for total proceeds exceeding $1.37 million.

Axsome Therapeutics' General Counsel, Hunter R. Murdock, reported the exercise of stock options and subsequent sale of common stock totaling 22,500 shares over three days in June 2025, all conducted under a pre-approved 10b5-1 trading plan.

Axsome Therapeutics, Inc. Director Mark Coleman was granted 3,166 stock options and 1,429 restricted stock units (RSUs) on June 6, 2025, as part of his compensation.

Axsome Therapeutics, Inc. Director Roger Jeffs was granted 3,166 stock options and 1,429 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Mark E. Saad, a Director at Axsome Therapeutics, Inc. (AXSM), was granted 3,166 stock options and 1,429 restricted stock units (RSUs) on June 6, 2025, as part of his compensation.

Axsome Therapeutics, Inc. Director Susan Mahony was granted 3,166 stock options and 1,429 restricted stock units on June 6, 2025, as part of her compensation.

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, executed a pre-planned transaction, exercising 25,000 stock options and subsequently selling the acquired common shares for a significant profit.

Mark Coleman, a Director at Axsome Therapeutics, sold a total of 7,500 shares of common stock over two days in late May, pursuant to a pre-approved 10b5-1 trading plan.

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, reported the exercise of stock options and subsequent sale of common stock totaling 40,673 shares over two days in late May, pursuant to a pre-approved 10b5-1 trading plan.

Director Mark Coleman of Axsome Therapeutics sold 3,000 shares of common stock at an average price of $107.491 on May 20, 2025.

Director Susan Mahony acquired 1,312 stock options in Axsome Therapeutics in lieu of cash compensation on February 21, 2025.

Director Roger Jeffs acquired 1,408 stock options in Axsome Therapeutics in lieu of cash compensation on February 21, 2025.

Director Mark E. Saad of Axsome Therapeutics acquired 1,494 stock options in lieu of cash compensation on February 21, 2025.